Roche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)
2026-07-02 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, July 2 , 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on July 2 , regarding the results of the global Phase III clinical trial (Krascendo1) evaluating the KRAS G12C inhibitor divarasib in previously treated KRAS G12C-positive non-small cell lung cancer . The detailed data will be presented at an upcoming medical meeting. Please refer to the link below for details of the media release: Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer https://www.roche.com/media/releases/med-cor-2026-07-02
The release as fetched from its publisher. chugai-pharm.co.jp ↗